PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
30.46%
Revenue growth of 30.46% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
41.93%
Gross profit growth of 41.93% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that could be built upon.
82.60%
EBIT growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.10%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
82.60%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.22%. Joel Greenblatt would see if unique processes drive exceptional profitability.
100.85%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.59%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
101.37%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.24%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
100.00%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.24%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
20.86%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
61.58%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-1.79%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
16.41%
FCF growth of 16.41% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.23%
OCF/share CAGR of 81.23% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
81.23%
OCF/share CAGR of 81.23% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
35.95%
3Y OCF/share growth of 35.95% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
100.20%
Net income/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 22.75% over a decade. Joel Greenblatt might see a standout compounder of earnings.
100.20%
5Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 7.84%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
101.39%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 19.24%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
172.44%
Equity/share CAGR of 172.44% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
172.44%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 9.21%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
350.35%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 8.99%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.68%
AR growth of 26.68% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-10.75%
Decreasing inventory while Drug Manufacturers - Specialty & Generic is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
100.93%
Asset growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.62%. Joel Greenblatt confirms strong expansions matched by adequate returns on those assets.
76.87%
BV/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median. Joel Greenblatt checks if consistent ROE or undervalued buybacks fuel this advantage.
No Data
No Data available this quarter, please select a different quarter.
42.65%
R&D growth of 42.65% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
3.32%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.